{'fraction_non_alphanumeric': 0.020955574182732608, 'fraction_numerical': 0.00586756077116513, 'mean_word_length': 5.2513089005235605, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Parameters of acute and chronic toxicity of the insecticidal preparation VEIS-2

The main safety indicators of the new preparation VEIS-2, containing natural or chemically modified avermectins as an active ingredient, when exposed to the skin of mammals, intended to protect the downy feather raw material from keratophagous insects, have been studied. It has been established that the VEIS-2 compositions containing abamectin or avermectin B1a hemisuccinate as an active principle have a mild irritating effect on the conjunctival mucosa of the rabbit eye. With single and multiple applications on the skin, the above compositions do not cause such functional and structural changes in the skin as edema, erythema, cracks, desquamation. The presence of skin-resorptive and allergenic action in the compositions of the VEIS-2 preparation with abamectin or hemisuccinate avermectin B1a using the "test tube method" in rats, as well as using the reaction of specific lysis of leukocytes (RSLL), has not been established. It was shown that the VEIS-2 composition based on avermectin complex has a more pronounced local irritant effect on laboratory animals in terms of toxicity and allergenicity.